Arthritis Drug Proven Effective Against Severe Depression
A surprising new approach to treating depression is showing promise. Rather than targeting brain chemicals like conventional drugs, this method works by calming the immune system.
In a small-scale clinical trial led by the University of Bristol and published in JAMA Psychiatry on 20 May, researchers found that an anti-inflammatory drug commonly used for rheumatoid arthritis effectively eased symptoms in treatment-resistant depression patients. The drug also reduced fatigue and anxiety while improving quality of life.
Most antidepressants currently work by targeting brain chemicals such as serotonin, dopamine, and norepinephrine. However, about a third of depression patients do not respond well to these medications.
In recent years, scientists have focused on inflammation as another factor. Research indicates one in three depression patients has high levels of inflammatory markers in their blood, with interleukin-6 (IL-6) being a key protein of concern.
To test whether blocking IL-6 could alleviate depression, researchers conducted a four-week randomised controlled trial with 30 participants suffering moderate to severe depression who had low inflammatory markers in blood tests. Fourteen received tocilizumab (an arthritis drug), while 16 received a saline placebo.
Despite the small sample size, results showed greater improvement in the tocilizumab group. Remission rates reached 54% in the treatment group compared to 31% in the placebo group.
Golam Khandakar, Professor of Psychiatry and Immunology at the University of Bristol and lead investigator of the study, called the findings a significant milestone. ‘This work represents a major step forward in developing new treatments for depression, particularly treatment-resistant cases affecting millions in the UK alone,’ he said. ‘It is one of the first randomised controlled trials testing immunotherapy for depression, the first to target IL-6R as a treatment, and the first to use a targeted approach to select patients most likely to benefit — all demonstrating success.’
Dr. Éimear Foley, the study’s lead researcher, added that the findings bring medicine closer to biologically personalised mental health care. ‘Depression is estimated to affect 10-20% of people worldwide during their lifetime, yet for many, current treatments are insufficient,’ she said. ‘Our study brings us closer to tailored depression treatment, where care is matched to an individual’s biology — helping us deliver the right treatment to the right patient at the right time.’
One participant expressed satisfaction with their involvement. ‘I’m glad to have taken part. Without research, medical progress cannot be made,’ they said.
Despite the promising results, researchers stress that larger-scale studies are needed before immunotherapy can become a standard treatment for widespread depression. The next step is a phase III clinical trial with a broader scope. (Science Daily/Z-2)